biOasis Technologies Inc. (TSX.V: BTI) (the “Company”) – is pleased to announce that it has closed its private placement announced on November 25, 2011. The Company has issued a total of 2,571,942 units (the “Units”) at a price of $0.45 per Unit for gross proceeds of $1,157,374. Each Unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company exercisable until November 30, 2013. The Warrants are exercisable at a price of $0.60 per Share if exercised at any time up to and including November 30, 2012 and at a price of $0.70 per Share if exercised at any time after November 30, 2012 until the expiry date of November 30, 2013. A cash finders’ fee of $75,268 was paid on a portion of the financing. All securities issued are subject to a hold period expiring March 31, 2012. The net proceeds from the sale of units have been added to working capital in furtherance of the Company's business.

biOasis Technologies Inc. (TSX: V BTI) is pleased to announce a non-brokered private placement of up to 2,250,000 units at a price of $0.45 per unit for gross proceeds of up to $1,012,500 with an overallotment of up to 20%. Each unit will consist of one common share and one full common share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company for a period of twenty four months from the Closing Date. The Warrants are exercisable at an exercise price of $0.60 per share for the first twelve months and at an exercise price of $0.70 per share for the subsequent twelve months. The proceeds from the sale of units will be added to working capital in furtherance of the Company's business.

biOasis Technologies Inc. (TSX:V.BTI) announced today that it has entered into a research, evaluation and option agreement with Shire Human Genetic Therapies, Inc. (Shire) to evaluate biOasis’s Transcend technology in the area of lysosomal storage disorders (LSDs). In connection with this agreement, biOasis and Shire are undertaking certain experiments at their own expense and Shire has been granted certain options to obtain a license to biOasis’ Transcend technology on mutually agreeable terms.

biOasis Technologies Inc. (TSX:V.BTI) today announced test results from its Transcend therapeutic development program directed towards the delivery of targeted therapeutic compounds to the brain which showed that Transcend can deliver an anti-amyloid beta antibody to the brain. The work was conducted on behalf of the Company by the National Research Council of Canada (NRC).

“The initial pilot BT2111 study results from BCCRC were very compelling and this prompted us to conduct additional work to confirm those initial findings," said Rob Hutchison, CEO. "As further support we also undertook preliminary confocal imaging at the James Hogg Research Centre of brain sections taken from animals that were administered BT2111 intravenously.

Vancouver, B.C. September 2nd, 2011 – biOasis Technologies Inc. (TSXV: BTI) announces that it has granted options to its officers, employees, consultants and members of the board of directors. A total of 2,275,000 options have been granted effective at the close of business on September 1st, 2011.

Vancouver, B.C. August 18th, 2011 – biOasis Technologies Inc. (TSX:V BTI) announces its board of directors elected by the shareholders at its recently held Annual General Meeting held July 26, 2011

This brain imaging study was conducted by the National Research Council of Canada (NRC) and involved intravenous administration to mice of fluorescently labeled BT2111 or trastuzumab alone. The measurement of fluorescent labeled BT2111 in the brain two hours post injection confirmed that trastuzumab was carried by Transcend across the blood-brain barrier In contrast trastuzumab by itself did not distribute to the brain tissue.

On August 5, 2011, the closing date, the Company paid $25,000 in cash and issued 350,000 warrants at an exercise price of $0.575 and 100,000 warrants at an exercise price of $0.50. Each warrant is exercisable into one common share of the Company for a period of five years from the date of issuance. All of the warrants issued are subject to a hold period expiring December 6, 2011.

Vancouver, BC – biOasis Technologies Inc. (TSXV:BTI) (the “Company”) announces that its wholly owned subsidiary biOasis Advanced Technologies Inc. has entered into a worldwide assignment (the “Assignment”) to acquire certain Intellectual Property. Pursuant to the Assignment, the Company will pay $25,000 in cash and will issue 350,000 warrants at an exercise price of $0.575 and 100,000 warrants at an exercise price of $0.50.